Extract
Cytori Begins Breast Reconstruction Study in Europe.
SAN DIEGO -- Cytori (NASDAQ:CYTX) received approval to begin its European stem and regenerative cell-enhanced breast reconstruction study in breast cancer patients who have undergone partial mastectomy. This is a post-market study designated as RESTORE II. C...
See the full content of this document
Sponsored links
